MRX-2843 (also known as MRX2843; UNC-2371) is a novel, potent and orally bioactive small-molecule inhibitor of MERTK and FLT3 with anticancer activity.

AMG 925 (also called FLX-925; AMG-925) is a novel, potent, selective and orally bioavailable FLT3/CDK4 dual inhibitor with potential antitumor activity.

TCS 359 (TCS-359) is a novel, ATP-competitive and selective fms-like/FLT3 kinase inhibitor with IC50 of 42 nM.

Tandutinib (formerly also known as MLN-518, CT-53518, D06005, NSC726292), a piperazinyl quinazoline, is a novel, potent and selective FLT3 inhibitor/antagonist with potential antitumor activity.

BPR1J-097 is a potent FLT3 inhibitor with an IC50 of 11 nM.

Merestinib (LY-2801653) is a novel, potent, orally bioavailable, type-II ATP competitive, slow-off small molecule inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min.

ATH686 is a novel and selective FLT3 Inhibitor.

Quizartinib (formerly also know as AC-220; AC-010220, brand name Vanflyta in Japan) is a novel, potent, 2nd-generation, and orally bioavailable FLT3 tyrosine kinase inhibitor for Flt3 (ITD/WT) with potential anticancer activity.

SKLB4771 (also known as FLT3-IN-1) is a novel, potent and selective inhibitor of FLT3 (fms-like tyrosine kinase 3) that may be potentially used for the treatment of cutaneous inflammation and psoriasis-like symptoms of disease.

UNC-2025 is a novel, potent and orally bioavailable dual inhibitor of MER/FLT3 with IC50 of 0.74 nM and 0.8 nM, respectively, it displayed about 20-fold selectivity over Axl and Tyro3.